136 related articles for article (PubMed ID: 907417)
21. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
Battistin L; Meneghetti G; Rigotti S; Saia A
Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
[TBL] [Abstract][Full Text] [Related]
22. [Sinomet and Madopar, a comparative study on the treatment of Parkinson's disease].
Lakke JP; Bissessur S; De Man JJ; Moll L; Seegers J; Wesseling H; Witt FG
Ned Tijdschr Geneeskd; 1976 Oct; 120(40):1672-8. PubMed ID: 790204
[No Abstract] [Full Text] [Related]
23. Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
Papavasiliou PS; Cotzias GC; Rosal VL; Miller ST
Arch Neurol; 1978 Dec; 35(12):787-91. PubMed ID: 363104
[TBL] [Abstract][Full Text] [Related]
24. Levodopa with benserazide or carbidopa in Parkinson disease.
Rinne UK; Mölsä P
Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
[TBL] [Abstract][Full Text] [Related]
25. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Greenacre JK; Coxon A; Petrie A; Reid JL
Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
[TBL] [Abstract][Full Text] [Related]
26. Update on drug treatment of Parkinsonism.
Winkelman AC
Am Fam Physician; 1977 Jul; 16(1):118-20. PubMed ID: 18001
[No Abstract] [Full Text] [Related]
27. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease.
Leibowitz M; Lieberman A
Neurology; 1975 Oct; 25(10):917-21. PubMed ID: 52131
[TBL] [Abstract][Full Text] [Related]
28. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
Chouza C; Romero S; Gomensoro JB
Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242
[TBL] [Abstract][Full Text] [Related]
29. How to achieve maximum benefit for the patient with Parkinson's disease.
Greer M
Geriatrics; 1976 Apr; 31(4):89-96. PubMed ID: 4356
[No Abstract] [Full Text] [Related]
30. [Controlled study on the possibilities of L-dopa in the residual extrapyramidal syndrome caused by neuroleptics].
Gutiérrez M; Alpert M; Guimón J; Friedhoff AJ; Veramendi V
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1979; 7(3):181-8. PubMed ID: 382762
[No Abstract] [Full Text] [Related]
31. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
Rondot P; Ribadeau Dumas JL; Cardon P
Therapie; 1975; 30(5):653-66. PubMed ID: 769245
[No Abstract] [Full Text] [Related]
32. The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
Couto B; Oliveira C; Mattos JP; Freitas MR
Neurol Neurocir Psiquiatr; 1976; 17(4):285-92. PubMed ID: 798128
[TBL] [Abstract][Full Text] [Related]
33. Drug therapy of Parkinsonism dopaminergic drugs.
Bianchine JR
Ohio State Med J; 1977 Feb; 73(2):84-5. PubMed ID: 834419
[No Abstract] [Full Text] [Related]
34. [Autoimmune hemolytic anemia in a Parkinsonian treated with a combination of L-dopa and carbidopa].
Barat M; Conte P; Hilaire J; Arne L
Nouv Presse Med; 1977 Jul 2-9; 6(27):2442. PubMed ID: 896426
[No Abstract] [Full Text] [Related]
35. Electroencephalographic change in Parkinsonian patients treated with levodopa-carbidopa.
Stephens R; Green J; Haycook W; Kilgore M
Clin Electroencephalogr; 1979 Jan; 10(1):31-4. PubMed ID: 445860
[TBL] [Abstract][Full Text] [Related]
36. Levodopa in the treatment of Parkinson's disease.
Lloyd KG
Prim Care; 1977 Sep; 4(3):541-60. PubMed ID: 264229
[TBL] [Abstract][Full Text] [Related]
37. The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.
Rivera-Calimlim L; Tandon D; Anderson F; Joynt R
Arch Neurol; 1977 Apr; 34(4):228-32. PubMed ID: 843257
[TBL] [Abstract][Full Text] [Related]
38. Reversible haemolytic anaemia after levodopa-carbidopa.
Bernstein RM
Br Med J; 1979 Jun; 1(6176):1461-2. PubMed ID: 466061
[No Abstract] [Full Text] [Related]
39. [Stimulation of the secretion of somatotropin by administration of Nacom (L-dopa and L-carbidopa) in ambulatory patients with retarded growth].
Schönberger W; Grimm W; Ziegler R; Brodt B
Monatsschr Kinderheilkd (1902); 1977 May; 125(5):485-7. PubMed ID: 876212
[No Abstract] [Full Text] [Related]
40. Parkinson's disease.
Morley JB
Aust Fam Physician; 1977 Jan; 6(1):29-30, 32, 34-5. PubMed ID: 16582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
